The gene-editing transfection chemicals market will grow to $1.45B by 2029 at 7.8% CAGR, fueled by gene editing in therapies, biotech investments, non-viral delivery, and nanotech integration.
Read More
The gastrointestinal therapeutics market will reach $52.41B by 2029 at 5.5% CAGR, fueled by biologics, personalized medicine, microbiome therapies, digital health, and innovative acid suppression.
Read More
RNA therapy clinical trials market to reach $3.25 bn by 2029 at 4.8% CAGR, driven by rising burden of infectious diseases and rapid therapeutic development.
Read More
The gastric cancer therapy market will reach $6.39B by 2029 at 9.1% CAGR, driven by biomarker therapies, combination treatments, AI diagnostics, liquid biopsies, and personalized medicine.
Read More
The eye allergy therapeutics market will reach $4.10B by 2029 at 6.1% CAGR, driven by aging populations, biologics adoption, ophthalmic research, personalized medicine, and drug delivery innovations.
Read More
PD-1 non-small cell Lung cancer market to reach $38.26 bn by 2029 at 8.6% CAGR, driven by personalized treatments and clinical advancements.
Read More
Primary biliary cholangitis therapeutics market to reach $1.64 bn by 2029 at 12.9% CAGR, driven by rise in liver diseases and novel therapies.
Read More
Pregnancy care products market to reach $40.35 bn by 2029 at 6.0% CAGR, driven by rising birth rates and maternal health awareness.
Read More
The estrogen replacement therapy market will reach $11.97B by 2029 at 4.8% CAGR, driven by rising early menopause, contraceptive use, personalized therapy, digital health, and bioidentical hormones.
Read More
The environmental biotechnology market will grow to $29.61B by 2029 at 17.3% CAGR, driven by climate change mitigation, bioeconomy investment, eco-friendly processes, and enzyme-based soil detoxification.
Read More